Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of CareDx, Inc. (CDNA) Investigation
NEW YORK, NY / ACCESSWIRE / October 29, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CareDx, Inc. ("CareDx" or the "Company") (NASDAQ:CDNA). Investors who purchased CareDx sharesare encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cdna.
The investigation concerns whether CareDx and certain of its officers and/or directors have violated federal securities laws.
On October 28, 2021, CareDx issued a press release announcing its financial and operating results for the third quarter of 2021 and filed a quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission ("SEC"). In its 10-Q, CareDx disclosed that "the Company recently received a civil investigative demand (CID) from the United States Department of Justice (DOJ) requesting that the Company produce certain documents in connection with a False Claims Act investigation being conducted by the DOJ regarding certain business practices related to our kidney testing and phlebotomy services, and a subpoena from the United States Securities and Exchange Commission (SEC) in relation to an investigation by the SEC in respect of matters similar to those identified in the CID, as well as certain of our accounting and public reporting practices. The Company also received an information request from a state regulatory agency and may receive additional requests for information from the DOJ, SEC, or other regulatory and governmental agencies regarding similar or related subject matters." On this news, CareDx's stock price fell sharply during intraday trading on October 29, 2021.
If you are aware of any facts relating to this investigation, or purchased CareDx shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/cdna. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View source version on accesswire.com:
https://www.accesswire.com/670395/Bronstein-Gewirtz-Grossman-LLC-Notifies-Shareholders-of-CareDx-Inc-CDNA-Investigation
